Justin Gover - GW Pharmaceuticals CEO, Director
CEO
Mr. Justin Gover is Chief Executive Officer, Director of GW Pharmaceuticals PLC. He has 17 years experience in the pharmaceutical industry. As Chief Executive Officer, he was the lead executive responsible for the running of our company operations, as well as in leading equity financings and business development activities. Prior to joining our company, Mr. Gover was Head of Corporationrationrate Affairs at Ethical Holdings plc from 1995 to 1997 where he was responsible for the company strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations since 1999.
Age | 42 |
Tenure | 25 years |
Professional Marks | MBA |
Phone | (44) 1223 235667 |
Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 9 records | CEO Age | ||
Yaron Ravkaie | Radcom | 48 | |
Brendan Whitworth | Anheuser Busch Inbev | 45 | |
Bernardo Paiva | Ambev SA ADR | 45 | |
Carlos Brito | Anheuser Busch Inbev | 60 | |
Jean Neto | Ambev SA ADR | 50 | |
Joao Neves | Ambev SA ADR | N/A | |
David Ripstein | Radcom | 47 | |
Gaofei Wang | Weibo Corp | 45 | |
George Cope | BCE Inc | 56 |
Management Performance
Return On Equity | -7.92 | |||
Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director | ||
Christopher Tovey, COO, Executive Director | ||
Thomas Lynch, Non-Executive Independent Director | ||
Catherine Mackey, Non-Executive Independent Director | ||
Justin Gover, CEO, Director | ||
Geoffrey Guy, Executive Chairman of the Board | ||
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
Julian Gangolli, Executive Director | ||
Alicia Secor, Non-Executive Independent Director | ||
Adam George, CFO, Company Secretary, Director | ||
Cabot Brown, Non-Executive Independent Director | ||
Stephen Wright, Research & Development Director, Executive Director | ||
Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -7.92 | |||
Return On Asset | -3.55 | |||
Profit Margin | (11.03) % | |||
Operating Margin | (9.82) % | |||
Current Valuation | 6.42 B | |||
Shares Outstanding | 31.54 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 80.35 % | |||
Number Of Shares Shorted | 693.73 K | |||
Price To Earning | 126.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |